Treatment Protocol to Monitor the Safety of a 200 mg Dose of Bicalutamide in Patients With Advanced Prostate Cancer
Status:
Completed
Trial end date:
2013-06-01
Target enrollment:
Participant gender:
Summary
This is an open label, single-centered treatment protocol designed to monitor the safety of
patients treated with a 200 mg daily dose of CASODEX. Patient will receive CASODEX as long as
physician feels that he is benefiting from this form of therapy.